BioSpace News Archive

Series B investors include venture capital, industry, academia, patient advocacy groups and philanthropy

Bristol-Myers Squibb Company reported results for the third quarter of 2019, which were highlighted by strong sales and a robust operating performance, along with the continuing advancement of the company’s pipeline.

Analyses of tebentafusp data provide further insight into platform’s mechanism of action, potential link to clinical activity in uveal melanoma

Obalon Therapeutics, Inc. announces that it plans to release its third quarter 2019 financial results before the market opens on Friday, November 8, 2019 and hold a conference call at 9:00 AM Eastern Time to discuss the Company’s financial results and provide a business update.

The government of the Democratic Republic of the Congo (DRC) has decided to use the investigational Ebola vaccine regimen currently being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson as part of an expanded public health initiative to help contain the country’s Ebola outbreak

Three cardiac surgeons at Cleveland Clinic, Hackensack Meridian Health and Cedars-Sinai Medical Center are the first in the United States to implant Abiomed’s newest heart pump, the Impella 5.5 with SmartAssist. Ed Soltesz, MD, Mark Anderson, MD, and Danny Ramzy, MD, have each successfully implanted multiple pumps during cardiac procedures at their hospitals..

Indivior PLC (LON: INDV) today announced that its Q3/YTD 2019 results press release and investor supplement are now available via the London Stock Exchange’s Regulatory News Service (RNS) and on the “Investors” section of the company’s website at www.indivior.com.

Vertex Pharmaceuticals (Europe) Limited today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for the VX-445 (elexacaftor), tezacaftor and ivacaftor triple combination regimen.

NexImmune, a clinical stage immunotherapy company developing novel T cell therapies, received Investigational New Drug (IND) clearance for the company’s first cellular therapy product

In addressing a highly prevalent, non-monogenic musculoskeletal disease, FX201 has the potential to open a new treatment avenue for gene therapy